
|Slideshows|July 28, 2020
- MHE July 2020
- Volume 30
- Issue 7
MHE 2020 Annual Pharmacy Survey
Author(s)MHE Staff
As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. First of three parts. See more in our Surveys tab.
Advertisement
Overall, the responses paint a picture of the pandemic having a major impact, which is not surprising, and reveal some optimism; for example, 78% of the respondents expect to see at least limited use of a COVID-19 vaccine by the first quarter of 2021.
Articles in this issue
almost 6 years ago
Upping the Cardiovascular Health Gamealmost 6 years ago
MHE 2020 Annual Pharmacy Survey pt. 3almost 6 years ago
New Drugs Take Aim at Autoimmune Diseasesalmost 6 years ago
Is the Biosimilars Waiting Game Finally Over?almost 6 years ago
MHE 2020 Annual Pharmacy Survey pt. 2almost 6 years ago
Racial Disparities in Cancer Enter the Spotlightalmost 6 years ago
Opinion: The Future of Pharmacy Care Services, Post-Pandemicalmost 6 years ago
Has the C-Suite Gotten Too Big?almost 6 years ago
Protecting the Integrity of EHR Clinical Decision Support ToolsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5






















